Literature DB >> 7968277

Fluctuations in viremia, aminotransferases and IgM antibody to hepatitis B core antigen in chronic hepatitis B patients with disease exacerbations.

G C Mels1, G Bellati, G Leandro, M R Brunetto, O Vicari, M Borzio, P Piantino, G Fornaciari, G Scudeller, G Angeli.   

Abstract

We studied the relationships between the serum levels of viremia, aminotransferases and IgM anti-HBc, measured by monthly quantitative assays, in 52 untreated chronic hepatitis B patients (41 anti-HBe+, 11 HBeAg+) followed up for 12-20 months. Forty hepatitis exacerbations were observed in 17/41 anti-HBe+ (41.5%) and in 6/11 HBeAg+ patients (54.5%) (p = NS); all but one were clinically asymptomatic. We analyzed the fluctuations in the serum levels of the three parameters before, during and after the hepatitis exacerbations and found this chronological sequence of events in 96.2% of them: HBV-DNA increase-->ALT flare-->IgM anti-HBc increase. These results suggest that both antiviral immune reactions and ALT flares were triggered by quantitative variations in viremia. HBV-DNA baseline levels before flares were lower in anti-HBe+ (3.9 +/- 1.2 pg/ml) than in HBeAg+ patients (35.3 +/- 5.4 pg/ml) (p < 0.0001) and there was an inverse correlation between basal values and viremia level increases at the time of disease exacerbations (p < 0.001). This suggests that for a hepatitis exacerbation to occur, low basal viremia needed to increase markedly, while moderate increases in HBV-DNA serum levels were sufficient to trigger ALT flares in patients with elevated basal viremia. In conclusion, asymptomatic hepatitis B exacerbations are frequent in the natural history of chronic HBV infection, and monthly monitoring of HBV-DNA, ALT and IgM anti-HBc appears to be a suitable method to evaluate their frequencies and entities. This method can be a helpful guide for clinical and therapeutic decision-making in the single patient with chronic hepatitis B.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7968277     DOI: 10.1111/j.1600-0676.1994.tb00071.x

Source DB:  PubMed          Journal:  Liver        ISSN: 0106-9543


  13 in total

1.  Performance characteristics of microparticle enzyme and chemiluminescence immunoassays for measurement of anti-HBc immunoglobulin M in sera of patients with HBeAg-negative chronic hepatitis B virus infection.

Authors:  Emilia Hadziyannis; Emanuel Manesis; Dimitrios Vassilopoulos; Anastasia Georgiou; Athanasios Archimandritis
Journal:  Clin Vaccine Immunol       Date:  2007-12-12

2.  Association Between Severe Serum Alanine Aminotransferase Flares and Hepatitis B e Antigen Seroconversion and HBV DNA Decrease in Untreated Patients With Chronic HBV Infection.

Authors:  Mayur Brahmania; Manuel Lombardero; Bettina E Hansen; Norah A Terrault; Anna S Lok; Robert P Perrillo; Steven H Belle; Adrian M Di Bisceglie; Jordan J Feld; William M Lee; Michael W Fried; Harry L A Janssen
Journal:  Clin Gastroenterol Hepatol       Date:  2019-02-08       Impact factor: 11.382

3.  Increase in the frequency of hepadnavirus DNA integrations by oxidative DNA damage and inhibition of DNA repair.

Authors:  J Petersen; M Dandri; A Bürkle; L Zhang; C E Rogler
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

Review 4.  Acute exacerbation of chronic hepatitis B: the dilemma of differentiation from acute viral hepatitis B.

Authors:  Pankaj Puri
Journal:  J Clin Exp Hepatol       Date:  2013-10-17

5.  Differentiation of acute and chronic hepatitis B in IgM anti-HBc positive patients.

Authors:  Ji Won Park; Kyeong Min Kwak; Sung Eun Kim; Myoung Kuk Jang; Dong Joon Kim; Myung Seok Lee; Hyoung Su Kim; Choong Kee Park
Journal:  World J Gastroenterol       Date:  2015-04-07       Impact factor: 5.742

6.  Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon {alpha}-2b therapy.

Authors:  H J Flink; D Sprengers; B E Hansen; M van Zonneveld; R A de Man; S W Schalm; H L A Janssen
Journal:  Gut       Date:  2005-05-29       Impact factor: 23.059

7.  Comparative risk of liver-related mortality from chronic hepatitis B versus chronic hepatitis C virus infection.

Authors:  Oluwaseun Falade-Nwulia; Eric C Seaberg; Charles R Rinaldo; Sheila Badri; Mallory Witt; Chloe L Thio
Journal:  Clin Infect Dis       Date:  2012-04-20       Impact factor: 9.079

8.  A randomized, controlled study of thymosin-alpha1 therapy in patients with anti-HBe, HBV-DNA-positive chronic hepatitis B.

Authors:  C Zavaglia; R Severini; C Tinelli; J S Franzone; A Airoldi; S Tempini; G Bettale; G Ideo
Journal:  Dig Dis Sci       Date:  2000-04       Impact factor: 3.199

Review 9.  Transaminase Elevations during Treatment of Chronic Hepatitis B Infection: Safety Considerations and Role in Achieving Functional Cure.

Authors:  Andrew Vaillant
Journal:  Viruses       Date:  2021-04-23       Impact factor: 5.048

10.  Hospital-based surveillance for viral hemorrhagic fevers and hepatitides in Ghana.

Authors:  Joseph Humphrey Kofi Bonney; Mubarak Osei-Kwasi; Theophilus Korku Adiku; Jacob Samson Barnor; Robert Amesiya; Chrysantus Kubio; Lawson Ahadzie; Stephan Olschläger; Michaela Lelke; Beate Becker-Ziaja; Meike Pahlmann; Stephan Günther
Journal:  PLoS Negl Trop Dis       Date:  2013-09-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.